Option chain shows key data for New Pacific Metals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for New Pacific Metals.

New Pacific Metals (AMEX:NEWP) Stock, Option Chain

Newport Corporation

NASDAQ

New Pacific Metals

New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.

Newport

Earnings

News

Penny Stocks

Upgrades

Markets

Analyst Ratings

Trading Ideas

NEWP

New Pacific Metals Corp. (AMEX:NEWP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.

New Pacific Metals Moves to Buy: Rationale Behind the Upgrade

Screenshot 2024-05-29 at 5.35.33 PM

Commodities

ADVZF

PAAS

Precious metal prices are significantly influenced by investor sentiment, much like stocks and bonds. This can lead to routine price fluctuations, sometimes large and erratic, where the volatility can create both challenges and opportunities for investors. 

Silver Prices Surging – How Market Conditions Are Affecting The Price Of Silver

Eurozone

Small Cap

Global

Intraday Update

FEMY

IMVT

RNAZ

SLNO

UNFI

U.S. stocks traded lower toward the end of trading, with the Dow Jones falling more than 400 points on Tuesday.

The Dow traded down 1.19% to 33,601.60 while the NASDAQ fell 1.48% to 13,074.97. The S&amp;P 500 also fell, dropping, 1.42% to 4,276.00.

Nasdaq Down 1.5%; Immunovant Shares Spike Higher

New Pacific Metals Corp

Newpath Resources Inc

NEWPOINT FINL CORP by NEWPOINT FINL CORP.

Newpoint Financial Corp

NEWPORT EXPL LTD by Newport Exploration Ltd.

Newport Exploration Ltd

Newport Gold Inc

New Pacific Metals Announces Filing Of Preliminary Economic Assessment For The Carangas Project

Roth MKM analyst Joe Reagor maintains New Pacific Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NEWP#AMEX">NEWP</a>) with a Buy and lowers the price target from $6 to $5.

Price Target

Roth MKM Maintains Buy on New Pacific Metals, Lowers Price Target to $5

New Pacific Metals Corp. (AMEX:NEWP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.
A company&#39;s changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.
The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.
Therefore, the Zacks rating upgrade for New Pacific Metals basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.
Most Powerful Force Impacting Stock Prices
The change in a company&#39;s future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That&#39;s partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company&#39;s shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for New Pacific Metals imply an improvement in the company&#39;s underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
Harnessing the Power of Earnings Estimate Revisions
Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988.
Earnings Estimate Revisions for New Pacific Metals
For the fiscal year ending June 2024, this company is expected to earn -$0.03 per share, which is a change of 40% from the year-ago reported number.
Analysts have been steadily raising their estimates for New Pacific Metals. Over the past three months, the Zacks Consensus Estimate for the company has increased 14.3%.
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of &#39;buy&#39; and &#39;sell&#39; ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a &#39;Strong Buy&#39; rating and the next 15% get a &#39;Buy&#39; rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
The upgrade of New Pacific Metals to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
<a href="https://www.zacks.com/stock/news/2293855/new-pacific-metals-newp-moves-to-buy-rationale-behind-the-upgrade?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2293855">To read this article on Zacks.com click here.</a>

Roth MKM analyst Joe Reagor maintains New Pacific Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NEWP#AMEX">NEWP</a>) with a Buy and maintains $6 price target.

Roth MKM Maintains Buy on New Pacific Metals, Maintains $6 Price Target

New Pacific Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NEWP#AMEX">NEWP</a>) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year.

New Pacific Metals Q3 EPS $(0.01), Same YoY

New Pacific Metals Outline Its 2024 Plans For Its Operations In Bolivia

Options

NEPT

NKTX

NMRD

NRSN

NVCR

OBLG

OESX

OTLY

PCSA

PRFX

PRTG

PSNL

QNRX

RANI

RSLS

SLGL

SNAX

SNDX

SNOA

SNSE

SYBX

TBPH

TCON

THAR

TNXP

TOPS

VCNX

VERU

VMAR

VRAR

VVOS

Vintage Wine Estates, Inc. - Common Stock

XAIR

XWEL

Stocks That Hit 52-Week Lows On Friday

U.S. stocks traded lower toward the end of trading, with the Dow Jones falling more than 400 points on Tuesday.
The Dow traded down 1.19% to 33,601.60 while the NASDAQ fell 1.48% to 13,074.97. The S&amp;P 500 also fell, dropping, 1.42% to 4,276.00.
Check This Out: <a href="https://www.benzinga.com/news/23/09/34903660/draftkings-to-rally-around-35-here-are-10-other-analyst-forecasts-for-tuesday"> DraftKings To Rally Around 35%? Here Are 10 Other Analyst Forecasts For Tuesday</a>
&nbsp; 
<h3>Leading and Lagging Sectors</h3>

Energy shares fell by just 0.01% on Tuesday.
In trading on Tuesday, utilities shares tumbled by 2%.
&nbsp; 
<h3>Top Headline</h3>

United Natural Foods Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unfi#NYSE">UNFI</a>) reported mixed results for its fourth quarter on Tuesday.
United Natural Foods reported fourth-quarter FY23 sales growth of 2% year-on-year to $7.417 billion, missing the analyst consensus of $7.47 billion. Adjusted EPS of $(0.25) beat the analyst consensus estimate of $(0.28).
United Natural Foods sees FY24 sales of $30.9 billion-$31.5 billion, against the consensus of $31.03 billion. The company expects FY24 adjusted EPS of $(0.88)-$0.38 versus the consensus of $2.56.
&nbsp; 
<h3>Equities Trading UP</h3>

Soleno Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slno#NASDAQ">SLNO</a>) shares shot up 442% to $24.01 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi Syndrome.
Shares of Femasys Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/femy#NASDAQ">FEMY</a>) got a boost, shooting 260% to $1.1950 after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a woman&#39;s fallopian tube.
Immunovant, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imvt#NASDAQ">IMVT</a>) shares were also up, gaining 100% to $40.58. Alfasigma agreed to acquire Intercept Pharmaceuticals for $19.00 per share in cash.
&nbsp; 
<h3>Equities Trading DOWN</h3>

TransCode Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnaz#NASDAQ">RNAZ</a>) shares dropped 71% to $0.7306 after the company priced its $8 million public offering of 15.7 million shares at $0.51 per share.
Shares of United Natural Foods, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unfi#NYSE">UNFI</a>) were down 25% to $14.18 after the company reported mixed fourth-quarter financial results and issued guidance.
New Pacific Metals Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/newp#NYSE">NEWP</a>) was down, falling 13% to $1.9408. New Pacific Metals announced CAD$35 million bought deal financing.
Also Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/23/09/34905861/more-than-8m-bet-on-this-healthcare-stock-check-out-these-4-penny-stocks-insiders-are-ag"> More Than $8M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying</a>
&nbsp; 
<h3>Commodities</h3>

In commodity news, oil traded up 1% to $90.61 while gold traded down 0.9% at $1,920.10.
Silver traded down 1% to $23.155 on Tuesday while copper fell 0.6% to $3.6475.
&nbsp; 
<h3>Euro zone</h3>

European shares closed mostly lower today. The eurozone&rsquo;s STOXX 600 fell 0.61% London&rsquo;s FTSE 100 rose 0.02% while Spain&rsquo;s IBEX 35 Index fell 0.20% The German DAX fell 0.97% French CAC 40 declined 0.70%, while Italy&rsquo;s FTSE MIB Index fell 1%.
&nbsp; 
<h3>Asia Pacific Markets</h3>

Asian markets closed lower on Tuesday, with Japan&rsquo;s Nikkei 225 falling 1.11%, Hong Kong&rsquo;s Hang Seng Index falling 1.48% and China&rsquo;s Shanghai Composite Index declining 0.43%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, slipped 0.1%.
Hong Kong&rsquo;s trade deficit increased to $25.6 billion in August from $13.3 billion in the year-ago month. Imports to Hong Kong declined 0.3% year-over-year, while exports from Hong Kong fell 3.7% year-over-year in August.
&nbsp; 
<h3>Economics</h3>

U.S. building permits increased by 6.8% to an annual rate of 1.541 million in August, recording the highest level since October 2022.
The FHFA house price index rose by 0.8% from the previous month in July versus a revised 0.4% increase in June.
The S&amp;P CoreLogic Case-Shiller 20-city home price index rose 0.1% year-over-year in July, recording the first rise in five months, versus market expectations for a 0.3% decline.
Sales of new single-family houses fell by 8.7% to an annualized rate of 675,000 in August.
The Dallas Fed general business activity index for Texas&#39; service sector fell to a reading of -8.6 in September.
The manufacturing activity index in the Richmond area climbed to 5 in September versus August&rsquo;s reading of -7.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/09/34904604/top-4-materials-stocks-which-could-rescue-your-portfolio-this-month"> Top 4 Materials Stocks Which Could Rescue Your Portfolio This Month</a>
&nbsp; 
<h3>COVID-19 Update</h3>

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 108,602,110 cases with around 1,176,150 deaths. India confirmed a total of at least 44,998,560 cases and 531,930 deaths, while France reported over 40,138,560 COVID-19 cases with 167,640 deaths. In total, there were at least 695,750,000 cases of COVID-19 worldwide with more than 6,919,470 deaths.

<h3>Gainers</h3>
<ul>
<li>Soleno Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slno#NASDAQ">SLNO</a>) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi Syndrome.</li>
<li>Femasys Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/femy#NASDAQ">FEMY</a>) surged 244% to $1.1410 after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a woman&#39;s fallopian tube.</li>
<li>Intercept Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icpt#NASDAQ">ICPT</a>) shares gained 77.3% to $18.50. Alfasigma agreed to acquire Intercept Pharmaceuticals for $19.00 per share in cash.</li>
<li>Immunovant, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imvt#NASDAQ">IMVT</a>) jumped 75.6% to $35.60 after the company announced initial IMVT-1402 Phase 1 SAD and 300 mg subcutaneous MAD results.</li>
<li>Tharimmune Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/thar#NASDAQ">THAR</a>) shares gained 39.5% to $0.3090 after falling around 5% on Monday.</li>
<li>Acasti Pharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acst#NASDAQ">ACST</a>) gained 27.1% to $2.2250. Acasti announced a $7.5 million private placement equity financing.</li>
<li>Cano Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cano#NYSE">CANO</a>) surged 24.2% to $0.3380. Cano Health said it sold substantially all of the assets associated with the operation of Cano Health&#39;s senior-focused primary care centers in Texas and Nevada to CenterWell Senior Primary Care.</li>
<li>Bullfrog AI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfrg#NASDAQ">BFRG</a>) gained 23.6% to $3.5499. Bullfrog AI announced data from its preclinical study investigating the anti-cancer activity of a novel prodrug of mebendazole for glioblastoma.</li>
<li>Avalo Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avtx#NASDAQ">AVTX</a>) gained 21.9% to $0.1987 after jumping over 36% on Monday. Avalo Therapeutics reported the payoff of the remainder of its $35 million debt owed to Horizon Technology Finance.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adpt#NASDAQ">ADPT</a>) shares climbed 21.2% to $6.16. Adaptive recently announced the launch of Epic integration for clonoSEQ.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) shares gained 19.7% to $0.1561. Infobird recently announced receipt of delinquency notification letter from the Nasdaq.</li>
<li>ARS Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spry#NASDAQ">SPRY</a>) gained 18.8% to $4.28 after Director Rajeev Shah acquired a total of 2,700,000 shares an average price of $3.03 for roughly $8.18 million.</li>
<li>Roivant Sciences Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roiv#NASDAQ">ROIV</a>) gained 17% to $11.94 after the company announced initial IMVT-1402 Phase 1 SAD and 300 mg subcutaneous MAD results.</li>
<li>Verve Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/verv#NASDAQ">VERV</a>) rose 16.6% to $13.25. Verve Therapeutics to unveil interim data on VERVE-101 at the American Heart Association&#39;s Event.</li>
<li>Pliant Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plrx#NASDAQ">PLRX</a>) gained 15% to $16.77 after the company announced bexotegrast met its primary and secondary endpoints in the Phase 2a liver fibrosis trial.</li>
<li>Fisker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsr#NYSE">FSR</a>) rose 14.2% to $6.06 after the company announced that deliveries are set to ramp up.</li>
<li>Planet Green Holdings Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/plag#NYSE">PLAG</a>) surged 14.1% to $0.6470.</li>
<li>BYND Cannasoft Enterprises Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) rose 13.2% to $1.01.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adpt#NASDAQ">ADPT</a>) gained 12.4% to $5.71.</li>
<li>Acutus Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/afib#NASDAQ">AFIB</a>) jumped 11.7% to $0.6601.</li>
<li>Aclarion, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acon#NASDAQ">ACON</a>) gained 11.4% to $0.39.</li>
<li>Vera Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vera#NASDAQ">VERA</a>) climbed 10.3% to $15.69 as HC Wainwright &amp; Co maintained a Buy rating on the stock and raised its price target from $10 to $25.</li>
<li>Blue Star Foods Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bsfc#NASDAQ">BSFC</a>) rose 8.6% to $0.2520 after dipping 20% on Monday.</li>
<li>NightHawk Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nhwk#NASDAQ">NHWK</a>) gained 7.5% to $0.57.</li>
<li>Precigen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pgen#NASDAQ">PGEN</a>) rose 7.4% to $1.44.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>TransCode Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnaz#NASDAQ">RNAZ</a>) shares fell 68.7% to $0.7990 after the company priced its $8 million public offering of 15.7 million shares at $0.51 per share.</li>
<li>Murphy Canyon Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdt#NASDAQ">CDT</a>) fell 35.7% to $6.67 after dipping 38% on Monday.</li>
<li>Davis Commodities Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dtck#NASDAQ">DTCK</a>) declined 33.2% to $3.15. The company recently priced its IPO at $4 per share.</li>
<li>Molekule Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mkul#NASDAQ">MKUL</a>) fell 28.8% to $0.2064.</li>
<li>Polished.com Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pol#NYSE">POL</a>) fell 25.2% to $0.0928 after surging 40% on Monday.</li>
<li>United Natural Foods, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unfi#NYSE">UNFI</a>) fell 23.3% to $14.51 after the company reported mixed fourth-quarter financial results and issued guidance.</li>
<li>MicroAlgo Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mlgo#NASDAQ">MLGO</a>) fell 19.2% to $2.43.</li>
<li>Genetron Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gth#NASDAQ">GTH</a>) fell 18.2% to $0.7201.</li>
<li>Greenfire Resources Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gfr#NYSE">GFR</a>) declined 16.4% to $6.52.</li>
<li>Novo Integrated Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvos#NASDAQ">NVOS</a>) fell 14.9% to $0.2261.</li>
<li>Ebix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ebix#NASDAQ">EBIX</a>) dipped 12.8% to $10.36.</li>
<li>New Pacific Metals Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/newp#NYSE">NEWP</a>) declined 12.2% to $1.9487. New Pacific Metals announced CAD$35 million bought deal financing.</li>
<li>Greenfire Resources Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gfr#NYSE">GFR</a>) fell 11.5% to $6.90.</li>
<li>Biophytis S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpts#NASDAQ">BPTS</a>) fell 11.2% to $1.4099. Biophytis shares jumped over 72% on Monday after the company and Skyepharma announced a partnership agreement for the production of regulatory batches of Sarconeos (BIO101) for severe forms of Covid-19.</li>
<li>Roadzen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdzn#NASDAQ">RDZN</a>) fell 10.3% to $4.8135.</li>
<li>Akili, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akli#NASDAQ">AKLI</a>) declined 9.4% to $0.5130.</li>
<li>FaZe Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/faze#NASDAQ">FAZE</a>) shares fell 8.9% to $0.1749 after jumping 25% on Monday.</li>
<li>MSP Recovery, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lifw#NASDAQ">LIFW</a>) shares fell 7.8% to $0.1867 after declining around 15% on Monday.</li>
<li>TROOPS, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/troo#NASDAQ">TROO</a>) fell 6.4% to $3.8199.</li>
<li>Sacks Parente Golf, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spgc#NASDAQ">SPGC</a>) fell 6.3% to $1.2750. The company recently posted a narrower second-quarter loss.</li>
<li>TD SYNNEX Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snx#NYSE">SNX</a>) fell 5.2% to $96.64. TD Synnex reported a third-quarter revenue decline of 9.1% Y/Y to $13.96 billion, missing the consensus of $14.11 billion.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/23/09/34909189/ethereum-rises-but-remains-below-this-key-level-maker-emerges-as-top-gainer"> Ethereum Rises But Remains Below This Key Level; Maker Emerges As Top Gainer</a>

Movers

ACON

ACST

ADPT

AFIB

AKLI

AVTX

BCAN

BFRG

BPTS

BSFC

CANO

DTCK

EBIX

FAZE

ICPT

IFBD

LIFW

MKUL

MLGO

NHWK

NVOS

PGEN

PLAG

PLRX

RDZN

ROIV

SPGC

SPRY

TROO

VERA

VERV

Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday.
The Dow traded down 0.96% to 33,681.79 while the NASDAQ fell 1.24% to 13,106.70. The S&amp;P 500 also fell, dropping, 1.20% to 4,285.24.
Check This Out: <a href="https://www.benzinga.com/news/23/09/34903660/draftkings-to-rally-around-35-here-are-10-other-analyst-forecasts-for-tuesday"> DraftKings To Rally Around 35%? Here Are 10 Other Analyst Forecasts For Tuesday</a>
&nbsp; 
<h3>Leading and Lagging Sectors</h3>

Energy shares fell by just 0.4% on Tuesday.
In trading on Tuesday, communication services shares tumbled by 1.5%.
&nbsp; 
<h3>Top Headline</h3>

Cintas Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctas#NASDAQ">CTAS</a>) reported better-than-expected earnings for its first quarter on Tuesday.
The company posted first-quarter FY24 revenue growth of 8% year-on-year to $2.34 billion, meeting the analyst consensus estimate. EPS of $3.70 beat the analyst consensus estimate of $3.67.
Cintas raised FY24 revenue outlook from $9.35 billion - $9.50 billion to $9.40 billion - $9.52 billion, against the consensus of $9.50 billion. The company also raised FY24 EPS outlook from $13.85 - $14.35 to $14.00 - $14.45 versus an estimate of $14.42.
&nbsp; 
<h3>Equities Trading UP</h3>

Soleno Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slno#NASDAQ">SLNO</a>) shares shot up 385% to $21.48 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi Syndrome.
Shares of Femasys Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/femy#NASDAQ">FEMY</a>) got a boost, shooting 261% to $1.20 after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a woman&#39;s fallopian tube.
Immunovant, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imvt#NASDAQ">IMVT</a>) shares were also up, gaining 83% to $37.12. Alfasigma agreed to acquire Intercept Pharmaceuticals for $19.00 per share in cash.
&nbsp; 
<h3>Equities Trading DOWN</h3>

TransCode Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnaz#NASDAQ">RNAZ</a>) shares dropped 69% to $0.79 after the company priced its $8 million public offering of 15.7 million shares at $0.51 per share.
Shares of United Natural Foods, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unfi#NYSE">UNFI</a>) were down 23% to $14.63 after the company reported mixed fourth-quarter financial results and issued guidance.
New Pacific Metals Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/newp#NYSE">NEWP</a>) was down, falling 13% to $1.9310. New Pacific Metals announced CAD$35 million bought deal financing.
Also Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/23/09/34905861/more-than-8m-bet-on-this-healthcare-stock-check-out-these-4-penny-stocks-insiders-are-ag"> More Than $8M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying</a>
&nbsp; 
<h3>Commodities</h3>

In commodity news, oil traded up 0.7% to $90.33 while gold traded down 0.6% at $1,924.80.
Silver traded down 0.5% to $23.265 on Tuesday while copper fell 0.4% to $3.6540.
&nbsp; 
<h3>Euro zone</h3>

European shares were mostly lower today. The eurozone&rsquo;s STOXX 600 fell 0.42% London&rsquo;s FTSE 100 rose 0.18% while Spain&rsquo;s IBEX 35 Index rose 0.06% The German DAX fell 0.74% French CAC 40 declined 0.49%, while Italy&rsquo;s FTSE MIB Index fell 0.80%.
&nbsp; 
<h3>Asia Pacific Markets</h3>

Asian markets closed lower on Tuesday, with Japan&rsquo;s Nikkei 225 falling 1.11%, Hong Kong&rsquo;s Hang Seng Index falling 1.48% and China&rsquo;s Shanghai Composite Index declining 0.43%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, slipped 0.1%.
Hong Kong&rsquo;s trade deficit increased to $25.6 billion in August from $13.3 billion in the year-ago month. Imports to Hong Kong declined 0.3% year-over-year, while exports from Hong Kong fell 3.7% year-over-year in August.
&nbsp; 
<h3>Economics</h3>

U.S. building permits increased by 6.8% to an annual rate of 1.541 million in August, recording the highest level since October 2022.
The FHFA house price index rose by 0.8% from the previous month in July versus a revised 0.4% increase in June.
The S&amp;P CoreLogic Case-Shiller 20-city home price index rose 0.1% year-over-year in July, recording the first rise in five months, versus market expectations for a 0.3% decline.
Sales of new single-family houses fell by 8.7% to an annualized rate of 675,000 in August.
The Dallas Fed general business activity index for Texas&#39; service sector fell to a reading of -8.6 in September.
The Manufacturing Activity Index in the Richmond area climbed to 5 in September versus August&rsquo;s reading of -7.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/09/34904604/top-4-materials-stocks-which-could-rescue-your-portfolio-this-month"> Top 4 Materials Stocks Which Could Rescue Your Portfolio This Month</a>
&nbsp; 
<h3>COVID-19 Update</h3>

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 108,602,110 cases with around 1,176,150 deaths. India confirmed a total of at least 44,998,560 cases and 531,930 deaths, while France reported over 40,138,560 COVID-19 cases with 167,640 deaths. In total, there were at least 695,750,000 cases of COVID-19 worldwide with more than 6,919,470 deaths.

CTAS

Crude Oil Moves Higher; Cintas Earnings Top Estimates

WIIM

New Pacific Metals shares are trading lower after the company announced C$35 million in bought deal financing.

New Pacific Metals Corp. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NUAG#TSX">NUAG</a>, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEWP#NYSE">NEWP</a>) ("New Pacific" or the "Company") announced today that it has entered into an agreement with a syndicate of underwriters (the "Underwriters"), pursuant to which the Underwriters have agreed to purchase, on a bought deal basis, 13,208,000 common shares of the Company (the "Common Shares") at a price of C$2.65 per Common Share, for total gross proceeds of approximately C$35 million (the "Offering"). The Company will also grant to the Underwriters an over-allotment option (the "Over-Allotment Option") to purchase up to 1,981,200 additional Common Shares (the "Over-Allotment Shares"). The Over-Allotment Option will be exercisable for a period of 30 days following closing. &nbsp;
Silvercorp Metals Inc. ("Silvercorp") has indicated its intent to participate in the Offering by subscribing to 2,541,890 Common Shares representing approximately US$5 million in gross proceeds (approximately C$6.7 million). Upon completion of the Offering, Silvercorp will own, directly and indirectly, approximately 27.4% of the outstanding Common Shares of the Company assuming the Over-Allotment is not exercised.
In addition, Pan American Silver Corp. ("Pan American") has indicated its intent to participate in the Offering by subscribing to 5,083,780 Common Shares representing approximately US$10 million in gross proceeds (approximately C$13.5 million). Upon completion of the Offering, Pan American will own, directly and indirectly, approximately 11.6% of the outstanding Common Shares of the Company assuming the Over-Allotment is not exercised.
The Common Shares will be offered in all of the provinces of Canada, except the province of Québec, by way of a prospectus supplement (the "Supplement") to the Company's existing short form base shelf prospectus dated August 16, 2023 (the "Base Shelf Prospectus") and may also be offered by way of private placement in the United States, pursuant to registration exemptions.
The net proceeds of the Offering will be used to advance exploration and development at the Company's Silver Sand and Carangas projects, for working capital, and for general corporate purposes.
The Offering is expected to close on or about September 29, 2023, and is subject to New Pacific receiving all necessary regulatory approvals, including the approval of the Toronto Stock Exchange and the Common Shares having been approved for listing on the NYSE American.
No securities regulatory authority has either approved or disapproved of the contents of this news release. The Common Shares being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or the securities laws of any state of the United States and may not be offered, sold or delivered, directly or indirectly, in the United States or to or for the account or benefit of U.S. persons, absent registration or an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release shall not constitute an offer to sell or the solicitation of an offer to buy Common Shares in any jurisdiction, nor shall there be any sale of the Common Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful.
Silvercorp is a related party of the Company for the purposes of National Instrument 61-101 — Protection of Minority Security Holders in Special Transactions ("NI 61-101") and the acquisition by Silvercorp of Common Shares pursuant to the Offering is a related party transaction. The acquisition by Silvercorp of Common Shares pursuant to the Offering is exempt from the valuation and minority approval requirements of NI 61-101 pursuant to the exemptions in Sections 5.5(a) and 5.7(a) of NI 61-101.

Financing

TSX:NUAG

Reported September 25, New Pacific Metals Announces CAD$35M Bought Deal Financing

Roth MKM analyst Joe Reagor maintains New Pacific Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NEWP#AMEX">NEWP</a>) with a Buy and raises the price target from $4.75 to $6.

Roth MKM Maintains Buy on New Pacific Metals, Raises Price Target to $6

New Pacific Metals Q4 EPS $(0.01), Same YoY

U.S. stocks traded lower, with the Nasdaq Composite dropping around 50 points on Friday. Here are some big stocks recording gains in today&rsquo;s session.
<ul>
<li>PLAYSTUDIOS, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/myps#NASDAQ">MYPS</a>) jumped 20.5% to $4.1814 after reporting upbeat quarterly results.</li>
<li>PlayAGS, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ags#NYSE">AGS</a>) shares rose 18.3% to $7.51 after the company posted better-than-expected Q4 results.</li>
<li>Riskified Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rskd#NYSE">RSKD</a>) surged 14.7% to $6.17. Piper Sandler upgraded Riskified from Neutral to Overweight and raised the price target from $6 to $8.</li>
<li>Intuitive Machines, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lunr#NASDAQ">LUNR</a>) climbed 12.4% to $18.21 after gaining around 58% on Thursday.</li>
<li>Opera Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opra#NASDAQ">OPRA</a>) jumped 11.3% to $9.53. Opera recently reported better-than-expected Q4 financial results.</li>
<li>Theriva Biologics, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tovx#NYSE">TOVX</a>) gained 11% to $0.82.</li>
<li>HCI Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hci#NYSE">HCI</a>) rose 10.7% to $58.33 after reporting a profit for the fourth quarter.</li>
<li>Stratasys Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ssys#NASDAQ">SSYS</a>) gained 10.2% to $15.44 after Nano Dimension announced a formal offer to acquire the company for $18 per share.</li>
<li>Smith &amp; Wesson Brands, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swbi#NASDAQ">SWBI</a>) rose 9.5% to $11.38 following strong Q3 results.</li>
<li>DRDGOLD Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/drd#NYSE">DRD</a>) gained 9% to $7.38.</li>
<li>New Pacific Metals Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/newp#NYSE">NEWP</a>) rose 7.6% to $2.3999.</li>
<li>National Beverage Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fizz#NASDAQ">FIZZ</a>) gained 7.2% to $49.65 following upbeat quarterly results.</li>
<li>Target Hospitality Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/th#NASDAQ">TH</a>) rose 6.5% to $16.78 following Q4 results.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/markets/cryptocurrency/23/03/31296559/bitcoin-tumbles-below-this-key-level-conflux-huobi-token-among-top-losers"> Bitcoin Tumbles Below This Key Level; Conflux, Huobi Token Among Top Losers</a>

FIZZ

LUNR

MYPS

OPRA

RSKD

SSYS

SWBI

TOVX

Stratasys, PLAYSTUDIOS, PlayAGS And Other Big Stocks Moving Higher On Friday

CORRECTION: New Pacific Metals Q2 EPS $(0.01), Inline

New Pacific Metals Q2 EPS $(0.01), Inline

New Pacific Metals Corp. (&quot;New Pacific&quot; or the &quot;Company&quot;) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NUAG#TSX">NUAG</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEWP#NYSE">NEWP</a>) is pleased to announce the appointment of Mr.&nbsp;Andrew Williams&nbsp;to the position of President effective immediately.
Based in&nbsp;Vancouver&nbsp;and reporting to the CEO, Mr. Williams&#39; main responsibility will be&nbsp; managing the Company&#39;s corporate development initiatives, &nbsp;investor relationship&nbsp;program, and financial needs of the Company business. Mr. Williams will also work with CEO and other senior management to provide support for the development of the Company&#39;s projects in permitting, development and production and will assist CEO on team building and organization growth to support rapid growth of the Company&#39;s business.&nbsp;
Prior to joining New Pacific, Mr. Williams spent the last 11 years with SEC-registered investment fund Sun Valley Gold LLC, most recently as portfolio manager. Mr. Williams began his career at Deloitte providing audit and financial advisory services to mining companies in Vancouver.&nbsp; Mr. Williams holds a Bachelor of Commerce with Honours from the&nbsp;University of British Columbia&nbsp;and is a Chartered Professional Accountant and a Chartered Business Valuator.
Dr.&nbsp;Rui Feng, CEO and Founder of New Pacific, commented, &quot;We are very pleased to welcome Andrew to the New Pacific team. Andrew brings 15 years of experience in the mining and mining investment industry, most recently as a portfolio manager responsible for evaluating and investing in precious metals companies globally. Andrew&#39;s deep industry knowledge and strong relationships with mining investment community will make great contribution to the New Pacific&#39;s future growth.&quot;
&quot;I am excited to apply my knowledge and experience to help lead New Pacific, a rapidly growing company that has successfully completed the rare feat of making not one, but two important discoveries with the Silver Sand and Carangas projects,&quot; commented Mr. Williams. &quot;After recently completing two weeks of due diligence in&nbsp;Bolivia, seeing the projects firsthand and meeting the talented in-country team, I believe New Pacific has the potential to create tremendous value for all of its stakeholders. I am thrilled to be joining the Company at this pivotal stage of development.&quot;
Mr. Williams will subscribe for&nbsp;C$250,000&nbsp;worth of common shares of the Company at a price of&nbsp;$3.16&nbsp;per common&nbsp;share of the Company (10%&nbsp;discount of the 5 day volume-weighted average price) through a non-brokered private placement with the Company. &nbsp;The Company&#39;s newly elected Director, Mr.&nbsp;Dickson Hall&nbsp;will also subscribe, under the same terms,&nbsp;C$50,000&nbsp;worth of common shares of the Company for a total of&nbsp;C$300,000&nbsp;in this private placement.&nbsp; Mr. Williams and Mr.&nbsp;Dickson Hall&nbsp;are considered&nbsp; &quot;related parties&quot; of the Company, and the share purchase constitutes a &quot;related party transaction&quot; within the meaning of Multilateral Instrument 61-101 &ndash; Protection of Minority Security Holders in Special Transactions (&quot;MI 61-101&quot;). The Share Purchase is exempt from the formal valuation and the minority approval requirements of MI 61-101 as the fair market value of the consideration for the Share Purchase does not exceed&nbsp;25%&nbsp;of the Company&#39;s market capitalization.&nbsp;&nbsp; Closing of the Share Purchase is subject to the approval of the Toronto Stock Exchange.

Management

Reported Late Thursday, New Pacific Appoints Andrew Williams As President

<h3>Gainers</h3>
<ul>
<li>IceCure Medical Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iccm#NASDAQ">ICCM</a>) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who cannot be offered kidney-preserving surgery.</li>
<li>Avaya Holdings Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/avya#NYSE">AVYA</a>) gained 57% to $0.2384.</li>
<li>Athenex, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atnx#NASDAQ">ATNX</a>) surged 47% to $0.1991 after the company announced Quantum Leap Healthcare Collaborative reported a trial result of I-SPY2 trial for oral paclitaxel in combination with PD-1 and carboplatin in neoadjuvant breast cancer.</li>
<li>Verona Pharma plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrna#NASDAQ">VRNA</a>) shares climbed 40.5% to $18.71 after the company announced ensifentrine met primary and key secondary endpoints in the Phase 3 ENHANCE-1 trial for COPD.</li>
<li>Vallon Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vlon#NASDAQ">VLON</a>) shares climbed 33.9% to $0.4194. Vallon Pharmaceuticals and GRI Bio recently announced they entered into a merger agreement.</li>
<li>Dragonfly Energy Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dfli#NASDAQ">DFLI</a>) surged 29.7% to $25.95.</li>
<li>IAMGOLD Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/iag#NYSE">IAG</a>) gained 26.9% to $2.31 after the company announced a transaction with Sumimoto Metal Mining to provide up to $340 million in additional funding to the contruction of the C&ocirc;t&eacute; Gold Project. Also, the company announced an agreement to sell its Boto Gold Project and surrounding exploration assets to Managem for a total consideration of $282 million.</li>
<li>United Insurance Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uihc#NASDAQ">UIHC</a>) gained 24.7% to $0.6256. United Insurance Holdings Chief Operating Officer Christopher Griffith bought a total of 20,000 shares at an average price of $0.57.</li>
<li>Acasti Pharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acst#NASDAQ">ACST</a>) jumped 22.5% to $0.4899.</li>
<li>Alset Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aei#NASDAQ">AEI</a>) jumped 22% to $0.1849.</li>
<li>Core Scientific, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/corz#NASDAQ">CORZ</a>) gained 21.7% to $0.2463.</li>
<li>Baudax Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bxrx#NASDAQ">BXRX</a>) rose 20.7% to $2.22. Baudax Bio recently announced initiation of a Phase II clinical trial evaluationg BX1000 in patients undergoing surgery.</li>
<li>Smart for Life, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smfl#NASDAQ">SMFL</a>) rose 20.5% to $0.2415 after dropping 22% on Monday.</li>
<li>Exicure, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xcur#NASDAQ">XCUR</a>) shares gained 18.9% to $0.88. Exicure 10% owner CBI USA, Inc. acquired a total of 3,400,000 shares at an average price of $1.60.</li>
<li>Appreciate Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sfr#NASDAQ">SFR</a>) gained 18.4% to $1.48.</li>
<li>MediaAlpha, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/max#NYSE">MAX</a>) gained 17.5% to $18.71. JP Morgan upgraded MediaAlpha from Neutral to Overweight and raised the price target from $12 to $14.</li>
<li>Pagaya Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pgy#NASDAQ">PGY</a>) rose 17.2% to $0.6705.</li>
<li>EverQuote, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ever#NASDAQ">EVER</a>) shares climbed 15.4% to $18.71 after JPMorgan upgraded the stock from Underweight to Overweight and raised its price target from $8 to $15.</li>
<li>Hycroft Mining Holding Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hymc#NASDAQ">HYMC</a>) gained 15.2% to $0.5245.</li>
<li>Taseko Mines Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tgb#NYSE">TGB</a>) gained 14.8% to $1.4358 after the company announced it formed a strategic partnershi with Mitsui to develop the company&#39;s Florence Copper project.</li>
<li>Surrozen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srzn#NASDAQ">SRZN</a>) rose 14.5% to $0.55 after gaining 8% on Monday.</li>
<li>Mitsubishi UFJ Financial Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mufg#NYSE">MUFG</a>) rose 14.3% to $6.34.</li>
<li>Landos Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/labp#NASDAQ">LABP</a>) gained 14.3% to $0.4710.</li>
<li>DLocal Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dlo#NASDAQ">DLO</a>) gained 14% to $15.03 after the company refuted a short-seller report and announced a share buyback program and proposed share purchases by key share holders.</li>
<li>Metacrine, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtcr#NASDAQ">MTCR</a>) rose 13.6% to $0.3980. Tang Capital Partners reported in 13G filing a 7.1% stake in Metacrine.</li>
<li>Natura &amp;Co Holding S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ntco#NYSE">NTCO</a>) gained 12.6% to $4.37.</li>
<li>Sumitomo Mitsui Financial Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smfg#NYSE">SMFG</a>) rose 12.2% to $7.70.</li>
<li>Gol Linhas A&eacute;reas Inteligentes S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gol#NYSE">GOL</a>) gained 11.7% to $2.68.</li>
<li>Steelcase Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/scs#NYSE">SCS</a>) gained 11.6% to $6.98 after the company announced better-than-expected Q3 EPS results.</li>
<li>New Pacific Metals Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/newp#NYSE">NEWP</a>) jumped 11.4% to $2.4350.</li>
<li>Vivos Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vvos#NASDAQ">VVOS</a>) gained 11.3% to $0.5475.</li>
<li>TAL Education Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tal#NYSE">TAL</a>) rose 11.3% to $9.02.</li>
<li>Coeur Mining, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cde#NYSE">CDE</a>) gained 8.7% to $3.41.</li>
</ul>
<h3>
Losers</h3>
<ul>
<li>Caravelle International Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/caco#NASDAQ">CACO</a>) shares dipped 57.9% to $2.03 after declining over 12% on Monday.</li>
<li>Magenta Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgta#NASDAQ">MGTA</a>) dropped 44% to $0.4650 after the company reported it stopped dosing participants at the Cohort 4 dosing level and plans to dose additional participants at the Cohort 3 dosing level due to dose-limiting toxicities.</li>
<li>Entrada Therapeutics Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trda#NASDAQ">TRDA</a>) fell 33.5% to $13.22 after the company said it received a clinical hold notice from the FDA regarding its Investigational New Drug Application for ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy.</li>
<li>Axcella Health Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axla#NASDAQ">AXLA</a>) shares fell 29.1% to $0.3048 after gaining 165% on Monday. Axcella Health recently announced organizational and program updates, including a reprioritization of its programs for Long COVID Fatigue and Nonalcoholic Steatohepatitis (NASH) and a restructuring of operations.</li>
<li>Arcus Biosciences, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rcus#NYSE">RCUS</a>) fell 28.1% to $21.92. Gilead Sciences and Arcus Biosciences announced results from the fourth interim analysis of the ARC-7 Phase 2 study for metastatic non-small cell lung cancer with PD-L1 tumor proportion score &ge;50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations.</li>
<li>BioVie Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bivi#NASDAQ">BIVI</a>) fell 27% to $7.27.</li>
<li>Soleno Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slno#NASDAQ">SLNO</a>) shares fell 26.3% to $1.3599. Soleno Therapeutics shares jumped around 104% on Monday after the company announced a financing commitment for up to $60 million..</li>
<li>AppTech Payments Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apcx#NASDAQ">APCX</a>) fell 24.4% to $1.0583 after jumping 55% on Monday.</li>
<li>Kineta Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ka#NASDAQ">KA</a>) fell 24.4% to $3.76.</li>
<li>Cosmos Health Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cosm#NASDAQ">COSM</a>) dropped 22% to $5.91. Cosmos Health recently announced pricing of a $32.5 million registered direct offering and concurrent private placement priced at-the-market.</li>
<li>Prenetics Global Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pre#NASDAQ">PRE</a>) fell 20.4% to $1.91.</li>
<li>Camber Energy, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cei#NYSE">CEI</a>) fell 20% to $0.0857. Camber Energy shares jumped 73% on Monday after the company announced an anticipated effective date of December 21, 2022 for its previously-announced 1-for-50 reverse stock split.</li>
<li>Crown ElectroKinetics Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crkn#NASDAQ">CRKN</a>) fell 18.2% to $0.1451 after dropping 13% on Monday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.</li>
<li>Agrify Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agfy#NASDAQ">AGFY</a>) dropped 17.8% to $0.2750.</li>
<li>NantHealth, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nh#NASDAQ">NH</a>) shares fell 17.4% to $3.4801 after dropping 26% on Monday. NantHealth recently announced a 1-for-15 reverse stock split.</li>
<li>WaveDancer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wavd#NASDAQ">WAVD</a>) dipped 15.7% to $0.3975.</li>
<li>Duos Technologies Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/duot#NASDAQ">DUOT</a>) dropped 14.9% to $2.05.</li>
<li>Embecta Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/embc#NASDAQ">EMBC</a>) fell 14.8% to $27.65 after the company reported a decline in Q4 sales.</li>
<li>Vigil Neuroscience, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vigl#NASDAQ">VIGL</a>) dropped 14.5% to $10.51.</li>
<li>MicroAlgo Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mlgo#NASDAQ">MLGO</a>) declined 14.3% to $1.44.</li>
<li>Mullen Automotive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/muln#NASDAQ">MULN</a>) fell 14.1% to $0.2330.</li>
<li>Leju Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/leju#NYSE">LEJU</a>) dropped 13.5% to $1.35.</li>
<li>Allarity Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/allr#NASDAQ">ALLR</a>) fell 13.4% to $0.3031.</li>
<li>Ark Restaurants Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arkr#NASDAQ">ARKR</a>) dropped 13.1% to $15.74 after the company reported a sharp decline in quarterly earnings.</li>
<li>Embecta Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/embc#NASDAQ">EMBC</a>) fell 12.4% to $28.47 after the company reported Q4 earnings results.</li>
<li>ioneer Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ionr#NASDAQ">IONR</a>) dropped 12.3% to $11.96.</li>
<li>Reed&#39;s, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/reed#NASDAQ">REED</a>) fell 12% to $0.0889 after gaining around 35% on Monday.</li>
<li>Otonomy, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otic#NASDAQ">OTIC</a>) fell 9.6% to $0.1037. Otonomy&#39;s board of directors has approved and adopted a Plan of Liquidation and Dissolution that would include the distribution of remaining cash to stockholders following an orderly wind-down of the company&#39;s operations, including the proceeds from the sale of any pipeline assets.</li>
<li>Hoth Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hoth#NASDAQ">HOTH</a>) fell 9.5% to $2.68 after dropping 14% on Monday. Hoth Therapeutics recently announced submission of investigational new drug application for HT-001.</li>
<li>HTG Molecular Diagnostics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/htgm#NASDAQ">HTGM</a>) shares fell 8.7% to $0.7518 after jumping 49% on Monday.</li>
<li>Sintx Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sint#NASDAQ">SINT</a>) dropped 7% to $7.25. Sintx Technologies announced a 1-for-100 reverse stock split, effective December 20, 2022.</li>
</ul>
Also check this out <a href="https://www.benzinga.com/markets/cryptocurrency/22/12/30145338/ethereum-tops-1-200-chain-becomes-top-loser"> Ethereum Tops $1,200; Chain Becomes Top Loser</a>.

AGFY

ALLR

APCX

ARKR

ATNX

AVYA

AXLA

BIVI

BXRX

CACO

Core Scientific, Inc. - Class A Common Stock

CORZ

COSM

CRKN

DFLI

DUOT

EMBC

EVER

HOTH

HTGM

Hycroft Mining Holding Corporation - Class A Common Stock

HYMC

ICCM

IONR

LABP

LEJU

MGTA

MTCR

MUFG

MULN

NTCO

OTIC

RCUS

REED

SINT

SMFG

SMFL

SRZN

TRDA

UIHC

VIGL

VLON

VRNA

WAVD

XCUR

Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Madrigal Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdgl#NASDAQ">MDGL</a>) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.</li>
<li>Axcella Health Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axla#NASDAQ">AXLA</a>) shares rose 153% to $0.4105. Axcella Health shares dipped 63% on Friday after SVB Leerink downgraded the stock from Outperform to Market Perform and lowered its price target from $6 to $2.</li>
<li>Camber Energy, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cei#NYSE">CEI</a>) shares climbed 103% to $0.1257 after the company announced an anticipated effective date of December 21, 2022 for its previously-announced 1-for-50 reverse stock split.</li>
<li>Qumu Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qumu#NASDAQ">QUMU</a>) gained 98.2% to $0.8722 after Enghouse Systems announced it will acquire the company for $0.90 per share in cash.</li>
<li>AirNet Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ante#NASDAQ">ANTE</a>) jumped 64% to $1.93.</li>
<li>Viking Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vktx#NASDAQ">VKTX</a>) shares climbed 61% to $6.48 in sympathy with Madrigal Pharmaceuticals which announced a successful trial for liver fibrosis.</li>
<li>Nogin, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nogn#NASDAQ">NOGN</a>) rose 44% to $0.72 after declining 39% on Friday. Nogin&rsquo;s Co-CEO and President Jonathan Huberman recently acquired a total of 19,300 shares at an average price of $0.90.</li>
<li>Soleno Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slno#NASDAQ">SLNO</a>) surged 39% to $1.26 after the company announced a financing commitment for up to $60 million.</li>
<li>Terns Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tern#NASDAQ">TERN</a>) rose 39% to $9.55 in sympathy with Madrigal Pharmaceuticals, which gained after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.</li>
<li>Caravelle International Group (NASDAQ: CACO) gained 38.8% to $5.83.</li>
<li>Agrify Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agfy#NASDAQ">AGFY</a>) climbed 38% to $0.3410 after dipping around 70% on Friday. Agrify announced pricing of a public offering.</li>
<li>Innate Pharma S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ipha#NASDAQ">IPHA</a>) rose 37% to $2.6032 after the company and Sanofi announced an expansion of their collaboration for natural killer cell therapeutics in oncology. Innate will receive a &euro;25 million upfront payment.</li>
<li>Greenidge Generation Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gree#NASDAQ">GREE</a>) rose 30.3% to $0.3260 after dropping 39% on Friday.</li>
<li>Cazoo Group Ltd (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/czoo#NYSE">CZOO</a>) rose 24.4% to $0.1618. Cazoo recently sold its Spanish subscription business, Swipcar, to Renting Finders S.L.</li>
<li>Otonomy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otic#NASDAQ">OTIC</a>) rose 24.1% to $0.1118 after dropping over 21% on Friday.</li>
<li>Cerevel Therapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cere#NASDAQ">CERE</a>) gained 24% to $31.53 after the company said its Emraclidine Ambulatory Blood Pressuring Monitoring Trial did not cause an increase in blood pressure.</li>
<li>Aspen Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aspu#NASDAQ">ASPU</a>) gained 23.3% to $0.2833. Aspen Group recently reported better-than-expected Q2 sales results.</li>
<li>iHuman Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ih#NYSE">IH</a>) gained 21.2% to $2.80.</li>
<li>Anebulo Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aneb#NASDAQ">ANEB</a>) gained 20.3% to $2.84.</li>
<li>Future FinTech Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ftft#NASDAQ">FTFT</a>) jumped 19.1% to $0.5480.</li>
<li>Celcuity Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/celc#NASDAQ">CELC</a>) gained 19% to $11.91.</li>
<li>AppHarvest, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apph#NASDAQ">APPH</a>) rose 18.7% to $0.5563.</li>
<li>Troika Media Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trka#NASDAQ">TRKA</a>) rose 17.8% to $0.1178 after dropping around 6% on Friday.</li>
<li>Bird Global, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/brds#NYSE">BRDS</a>) gained 17.7% to $0.1765.</li>
<li>Professional Diversity Network, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ipdn#NASDAQ">IPDN</a>) surged 17.6% to $0.7771.</li>
<li>Argo Blockchain plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arbk#NASDAQ">ARBK</a>) rose 17.5% to $0.45 after declining 21% on Friday.</li>
<li>Horizon Global Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hzn#NYSE">HZN</a>) gained 16.7% to $0.70.</li>
<li>PainReform Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prfx#NASDAQ">PRFX</a>) gained 14% to $0.57.</li>
<li>Akili, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akli#NASDAQ">AKLI</a>) shares rose 14% to $1.14 after dipping 35% on Friday.</li>
<li>CI&amp;T Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cint#NYSE">CINT</a>) gained 12.8% to $5.89. CI&amp;T said that it has become an Amazon Web Services (AWS) Advanced Tier Services Partner within the AWS Partner Network.</li>
<li>Coeptis Therapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coep#NASDAQ">COEP</a>) rose 11.6% to $1.15 after dropping 36% on Friday.</li>
<li>Reading International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdib#NASDAQ">RDIB</a>) gained 10.2% to $19.77.</li>
<li>17 Education &amp; Technology Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/yq#NASDAQ">YQ</a>) rose 10.2% to $1.8286 after jumping 29% on Friday. 17 Education &amp; Technology recently posted a Q3 loss of $0.01 per share.</li>
<li>Summit Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smmt#NASDAQ">SMMT</a>) gained 10% to $3.9699.</li>
<li>Perfect Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/perf#NYSE">PERF</a>) gained 8.4% to $7.10.</li>
<li>ObsEva SA (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/obsv#NASDAQ">OBSV</a>) rose 6.6% to $0.1472. The company reported dismissal of moratorium proceedings.</li>
</ul>
<h3>
Losers</h3>
<ul>
<li>Cosmos Health Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cosm#NASDAQ">COSM</a>) shares dipped 59.6% to $9.30 after the company reported pricing of $32.5 million registered direct offering and concurrent private placement priced at-the-market.</li>
<li>Forward Pharma A/S (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fwp#NASDAQ">FWP</a>) fell 38.7% to $1.60. Forward Pharma announced expected delisting of its American Depositary Shares from the Nasdaq Capital Market.</li>
<li>Scopus BioPharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/scps#NASDAQ">SCPS</a>) fell 34.7% to $0.0556.</li>
<li>NantHealth, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nh#NASDAQ">NH</a>) fell 30.7% to $3.95. NantHealth recently announced a 1-for-15 reverse stock split.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zvsa#NASDAQ">ZVSA</a>) dropped 25.1% to $2.4109.</li>
<li>VistaGen Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtgn#NASDAQ">VTGN</a>) declined 25% to $0.1092. VistaGen Therapeutics recently announced the FDA granted Fast Track designation for the development of PH10 for the treatment of major depressive disorder.</li>
<li>Invacare Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ivc#NYSE">IVC</a>) dropped 25% to $0.4499.</li>
<li>Healthcare Triangle, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hcti#NASDAQ">HCTI</a>) fell 23.7% to $0.2364.</li>
<li>Lanvin Group Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lanv#NYSE">LANV</a>) fell 23% to $7.70 after surging 31% on Friday.</li>
<li>Neptune Wellness Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nept#NASDAQ">NEPT</a>) dropped 22.8% to $0.27. Neptune Wellness Solutions reported a net loss of $37.3 million for the fiscal second quarter 2023 versus a year-ago net loss of $12.1 million. Its net sales revenue declined to $12 million from $12.5 million.</li>
<li>PLDT Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/phi#NYSE">PHI</a>) dropped 22.4% to $20.81.</li>
<li>BiomX Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/phge#NYSE">PHGE</a>) shares fell 22.1% to $0.1720 after jumping 63% on Friday. BiomX, last month, posted a Q3 loss of $0.23 per share.</li>
<li>Tellurian Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tell#NASDAQ">TELL</a>) dropped 20.3% to $1.93.</li>
<li>Gossamer Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/goss#NASDAQ">GOSS</a>) declined 20.3% to $2.1750.</li>
<li>Akero Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akro#NASDAQ">AKRO</a>) fell 18.9% to $38.10.</li>
<li>Intercept Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icpt#NASDAQ">ICPT</a>) fell 18.8% to $12.45. STAT News reporter Adam Feuerstein tweets &quot;Intercept Pharmaceuticals Down 10% Because OCA&#39;s Future In NASH Looks Bleaker. Investors Really Want Intercept To Ditch NASH And Focus On The Approved PBC Indication.&quot;</li>
<li>TMC the metals company Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmc#NASDAQ">TMC</a>) dropped 17.9% to $0.5598.</li>
<li>Meihua International Medical Technologies Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mhua#NASDAQ">MHUA</a>) fell 17.8% to $9.28.</li>
<li>Nexa Resources S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nexa#NYSE">NEXA</a>) dropped 17.8% to $5.51.</li>
<li>Altimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alt#NASDAQ">ALT</a>) fell 17.2% to $9.51.</li>
<li>89bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etnb#NASDAQ">ETNB</a>) fell 16.8% to $8.78.</li>
<li>Vivani Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vani#NASDAQ">VANI</a>) dropped 16.7% to $0.8578.</li>
<li>Minim, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/minm#NASDAQ">MINM</a>) fell 16.5% to $0.1773 after jumping 22% on Friday.</li>
<li>Carvana Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cvna#NYSE">CVNA</a>) dropped 15.7% to $4.24.</li>
<li>Synaptogenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snpx#NASDAQ">SNPX</a>) fell 14.3% to $1.0228. Synaptogenix shares dropped 75% on Friday after the company announced results from its Phase 2 clinical trial of Bryostatin-1 for the treatment of advanced Alzheimer&#39;s disease, in which the primary endpoint was not met with statistical significance.</li>
<li>Cue Health Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hlth#NASDAQ">HLTH</a>) fell 14.2% to $2.5050.</li>
<li>C4 Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cccc#NASDAQ">CCCC</a>) dropped 14.1% to $6.32.</li>
<li>Seer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/seer#NASDAQ">SEER</a>) declined 13.6% to $5.40.</li>
<li>New Pacific Metals Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/newp#NYSE">NEWP</a>) fell 13.4% to $2.50.</li>
<li>Mondee Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mond#NASDAQ">MOND</a>) dropped 13.4% to $10.61.</li>
<li>Arcellx, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aclx#NASDAQ">ACLX</a>) fell 12.2% to $27.97.</li>
<li>Richardson Electronics, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rell#NASDAQ">RELL</a>) dropped 11.6% to $21.66.</li>
<li>Gevo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gevo#NASDAQ">GEVO</a>) fell 10.7% to $1.7950.</li>
<li>Cinemark Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cnk#NYSE">CNK</a>) fell 10.5% to $9.69.</li>
<li>Domo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/domo#NASDAQ">DOMO</a>) dropped 10.5% to $14.81. Morgan Stanley maintained Domo with an Overweight and lowered the price target from $51 to $24.</li>
<li>Mersana Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrsn#NASDAQ">MRSN</a>) dipped 10.5% to $5.82.</li>
<li>ChargePoint Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/chpt#NYSE">CHPT</a>) declined 9.6% to $9.45.</li>
<li>MasterBrand, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mbc#NYSE">MBC</a>) fell 9.5% to $8.42 after jumping over 20% on Friday.</li>
<li>Relay Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rlay#NASDAQ">RLAY</a>) dropped 9.4% to $15.44.</li>
<li>Melco Resorts &amp; Entertainment Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mlco#NASDAQ">MLCO</a>) fell 9.3% to $10.90.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amc#NYSE">AMC</a>) dropped 8.3% to $4.8650. AMC Entertainment announced Monday that it has raised $162 million from its AMC Preferred Equity Units since launching the stock just a few months ago.</li>
<li>Ardelyx, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ardx#NASDAQ">ARDX</a>) fell 7.9% to $1.8050 after the company provided an update regarding the appeal to the Complete Response Letter for the New Drug Application for XPHOZAH.</li>
<li>Mullen Automotive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/muln#NASDAQ">MULN</a>) fell 7.8% to $0.2787. Mullen Automotive recently announced it received a purchase order from Randy Marion Automotive Group for 6,000 Class 1 EV cargo vans.</li>
</ul>
Also check this out <a href="https://www.benzinga.com/trading-ideas/long-ideas/22/12/30127835/over-13-million-bet-on-this-biotechnology-stock-check-out-these-4-stocks-insiders-are-bu"> Over $13 Million Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying</a>.

ACLX

AKRO

ANEB

ANTE

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session

Comments

New Pacific Metals

New Pacific Metals (NEWP) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga